|
|
|
Insider
Information: |
Topper James N |
Relationship: |
|
City: |
Seattle |
State: |
WA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
14 |
|
Direct
Shares |
20,715,944 |
|
Indirect Shares
|
33,777,420 |
|
|
Direct
Value |
$195,395,319 |
|
|
Indirect Value
|
$517,185,955 |
|
|
Total
Shares |
54,493,364 |
|
|
Total
Value |
$712,581,273 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
3
|
1
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
3
|
0
|
|
|
|
Gain/Loss Ratio : |
-3.0
|
1.0
|
Percentage
Gain/Loss : |
-17.1%
|
0.5%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
La Jolla Pharmaceutical Co |
LJPC |
Director |
2005-12-14 |
0 |
2009-02-26 |
0 |
Premium* |
|
Amicus Therapeutics Inc |
FOLD |
Director, 10% Owner |
2007-06-05 |
0 |
2008-03-10 |
3,520,678 |
Premium* |
|
Portola Pharmaceuticals Inc |
PTLA |
Director |
2013-05-28 |
0 |
2013-05-28 |
1,428,954 |
Premium* |
|
Sierra Oncology Inc |
SRRA |
Director, 10% Owner |
2015-07-21 |
0 |
2017-02-14 |
8,112,121 |
Premium* |
|
Anaptysbio Inc |
ANAB |
Director |
2020-11-16 |
80,812 |
2020-11-16 |
199,529 |
Premium* |
|
Alpine Immune Sciences Inc |
ALPN |
Director |
2022-02-11 |
1,484,115 |
2024-05-18 |
0 |
Premium* |
|
Allena Pharmaceuticals, Inc. |
ALNA |
Director, 10% Owner |
2017-11-06 |
0 |
2017-11-06 |
3,330,373 |
Premium* |
|
Aptinyx Inc. |
APTX |
Director |
2018-06-25 |
0 |
2020-03-31 |
3,195,055 |
Premium* |
|
Entasis Therapeutics Holdings Inc. |
ETTX |
Director, 10% Owner |
2018-09-28 |
0 |
2018-09-28 |
1,349,953 |
Premium* |
|
Mirum Pharmaceuticals, Inc. |
MIRM |
10% Owner |
2019-07-22 |
3,566,912 |
2019-07-22 |
0 |
Premium* |
|
Arcutis Biotherapeutics, Inc. |
ARQT |
10% Owner |
2020-02-04 |
10,542,790 |
|
0 |
Premium* |
|
Passage Bio, Inc. |
PASG |
10% Owner |
2020-03-03 |
5,009,219 |
2020-03-03 |
0 |
Premium* |
|
Phathom Pharmaceuticals, Inc. |
PHAT |
|
2024-05-23 |
32,096 |
2024-05-23 |
5,831,328 |
Premium* |
|
Newamsterdam Pharma Ord Shs |
NAMS |
|
|
0 |
2024-03-26 |
6,809,429 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
95 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-03-03 |
4 |
B |
$9.83 |
$24,720,612 |
I/I |
18,426 |
829,518 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-28 |
4 |
B |
$9.84 |
$20,195 |
I/I |
2,038 |
753,019 |
2.17 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-03-04 |
4 |
B |
$9.85 |
$89,869 |
I/I |
9,000 |
843,018 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-21 |
4 |
B |
$9.86 |
$56,254 |
I/I |
5,500 |
701,167 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-03-06 |
4 |
B |
$9.90 |
$221,723 |
I/I |
22,146 |
915,164 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-04 |
4 |
B |
$9.92 |
$258,380 |
I/I |
25,352 |
395,667 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-11 |
4 |
B |
$9.93 |
$57,274 |
I/I |
5,700 |
608,267 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-08 |
4 |
B |
$9.94 |
$340,318 |
I/I |
33,800 |
602,567 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-27 |
4 |
B |
$9.95 |
$86,480 |
I/I |
8,600 |
750,981 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-07 |
4 |
B |
$9.96 |
$255,759 |
I/I |
25,400 |
568,767 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-28 |
4 |
B |
$9.97 |
$58,068 |
I/I |
5,762 |
758,781 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-03-10 |
4 |
B |
$9.98 |
$7,651 |
I/I |
760 |
915,924 |
2.17 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-12 |
4 |
B |
$9.99 |
$94,213 |
I/I |
9,400 |
617,667 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-26 |
4 |
B |
$9.99 |
$19,323 |
I/I |
1,900 |
727,681 |
2.17 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-06 |
4 |
B |
$10.00 |
$460,275 |
I/I |
45,477 |
543,367 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-22 |
4 |
B |
$10.09 |
$2,019 |
I/I |
200 |
709,981 |
2.17 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-13 |
4 |
B |
$10.10 |
$64,025 |
I/I |
6,200 |
623,867 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-05 |
4 |
B |
$10.16 |
$363,027 |
I/I |
35,536 |
465,026 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-03-10 |
4 |
B |
$10.19 |
$48,696 |
I/I |
4,740 |
920,664 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-01-31 |
4 |
B |
$10.21 |
$90,824 |
I/I |
8,800 |
290,315 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-04 |
4 |
B |
$10.32 |
$354,429 |
I/I |
33,823 |
429,490 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-05 |
4 |
B |
$10.32 |
$344,160 |
I/I |
32,864 |
497,890 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-13 |
4 |
B |
$10.44 |
$60,799 |
I/I |
5,800 |
629,667 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-15 |
4 |
B |
$10.47 |
$72,439 |
I/I |
6,900 |
636,567 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2007-06-27 |
4 |
B |
$10.95 |
$585,463 |
I/I |
52,788 |
144,400 |
2.25 |
- |
|
95 Records found
|
|
Page 3 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|